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SUMMARY. Eosinophilic infiltrate of liver tissue is described in
primary cholestatic diseases, hepatic allograft rejection and
drug-induced liver injury, but its significance and its impli-
cations in chronic hepatitis C are unknown. The aim of this
study was to investigate the clinical significance of eosino-
philic liver infiltrate in patients with chronic hepatitis C. We
retrospectively evaluated 147 patients with chronic hepatitis
C. The presence of eosinophilic infiltrate was investigated in
liver biopsies, and a numeric count of eosinophilic leucocytes
in every portal tract was assessed. An eosinophilic infiltrate
of liver tissue (‡3 cells evaluated in the portal ⁄ periportal
spaces) was observed in 46 patients (31%), and patients who
consumed drugs had an odds ratio (OR) of 4.02 (95% CI:
1.62–9.96) to have an eosinophilic infiltrate in liver biopsy.
By logistic regression analysis, the presence of steatosis was
independently associated with eosinophilic infiltrate (OR
5.86; 95% CI: 2.46–13.96) and homeostasis model assess-
ment-score (OR 1.18; 95% CI: 1.00–1.39). Logistic regres-
sion analysis also showed that fibrosis staging ‡ 2 by
Scheuer score was associated with grading >1 by Scheuer
score (OR 6.82; 95% CI 2.46–18.80) and eosinophilic infil-
trate (OR 4.00; 95% CI 1.23–12.91). In conclusion, we
observed that the eosinophilic infiltrate of liver tissue was
significantly more frequent in patients who assumed drugs,
and found a significant association between eosinophilic
infiltrate, liver steatosis and liver fibrosis. These preliminary
data could lead to a constant assumption of drugs as a co-
factor of eosinophils-mediated liver injury in chronic hepa-
titis C.
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liver biopsy, liver fibrosis, liver steatosis.
INTRODUCTION
Chronic hepatitis C in developed countries is a common
cause of chronic hepatic injury, liver transplantation and
liver related death [1]. In HCV hepatic disease, the co-factors
of liver damage are viral co-infections, liver steatosis, alcohol
abuse and liver iron overload [2]. The presence of concom-
itant diseases and, consequently, of chronic drug assumption
has not been investigated as a possible risk factor for severe
liver damage in chronic hepatitis C. In this context a tissue
infiltrate of eosinophilic leucocytes has very rarely been de-
scribed, and its significance is unknown. Conversely an
infiltration of eosinophilic leucocytes has been described in
various liver diseases, including primary biliary cirrhosis
(PBC) [3–9], primary sclerosing cholangitis (PSC) [10–12],
idiopathic hypereosinophilic syndrome [13–16], hepatic
allograft rejection [17–26], graft-vs-host disease [27] and
drug-induced liver injuries [28–34].
Experimental models have reported that activated Kupffer
cells play a key role in producing the cytotoxicity of eosin-
ophils by releasing TNF-a [35,36] a process that in evi-
denced, specifically, by liver biopsy of patients with drug-
induced liver injuries [37,38].
Our study was designed to examine the prevalence of
eosinophilic infiltrate (EI) in liver biopsies of patients with
chronic hepatitis C and to investigate the relations between
eosinophilic infiltration of liver tissue and clinical features,
current and ⁄ or recent assumption of drugs, and histological
features.
METHODS
Patients
We retrospectively analysed the clinical records of 335
consecutive patients with chronic hepatitis C admitted to
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our Liver Unit from January 2005 to December 2006 for
liver biopsy. Inclusion criteria of the patients were: (i)
HCV-RNA positive with histological diagnosis of chronic
hepatitis with any degree of fibrosis; (ii) a detailed phar-
macological anamnesis to define current and ⁄ or recent
assumption of drugs; (iii) availability of adequate liver
biopsy and serum stored upon admission to hospital for
histological and biochemical evaluations. Patients were
excluded if they had: (i) post-transplant recurrent hepatitis
C; (ii) chronic co-infection with HBV and ⁄ or HIV; (iii)
acute hepatitis; (iv) values of serum alanine aminotrans-
ferase (ALT) of more than 15 times the upper normal limit
(UNL); (v) an incomplete or absent anamnesis for con-
comitant diseases and ⁄ or drug assumption.
The current study was performed in accordance with the
principles of Good Clinical Practice, the principles of the
Declaration of Helsinki and its appendices, and local and
national laws. To maintain patient privacy, patients names
were replaced in the database with codes, dates of birth,
and ⁄ or ages.
Clinical and laboratory assessment
Upon admission to hospital, the age and gender of patients,
presence of other chronic diseases and a detailed pharma-
cologic anamnesis to define current and ⁄ or recent
assumption of drugs were recorded. After an overnight fast,
venous blood was drawn to evaluate the serum levels of
ALT, c-glutamyltransferase (c-GT), alkaline phosphatase
(AP), total cholesterol, triglycerides, plasma glucose con-
centration, platelet count and blood eosinophil count
(normal values < 550 cells ⁄ mm3). Serum insulin was
measured on stored serum by a two-site enzyme ELISA
(Mercodia Insulin ELISA, Arnika). The detection limit was
less than 1 lU ⁄ mL. Insulin resistance (IR) was determined
with the homeostasis model assessment (HOMA) method by
using the following equation: Insulin resistance (HOMA-
IR) = fasting insulin (lU ⁄ mL) · fasting glucose
(mmol ⁄ L) ⁄ 22.5 [39]. HOMA-IR has been validated in
comparison with euglycaemic ⁄ hyperinsulinaemic clamp
technique in both diabetic and non-diabetic subjects [40].
The same day, serum was collected to perform HCV RNA
qualitative PCR assay (Cobas Amplicor HCV Test version
2.0; limit of detection: 50 IU ⁄ mL) and to determine HCV
genotype by INNO-LiPA (HCV II, Bayer).
Assessment of liver biopsy
Percutaneous liver biopsies, performed with a 16-gauge
needle, were formalin fixed and paraffin embedded. We
used 4 lm sections that were rewashed, rehydrated and
stained with Hematoxylin-Eosin, Shikatas orcein, PAS
diastase and Gomori stain for reticular fibres. Slides of liver
specimens were coded and read by a single pathologist
(D.C.), who was unaware of patients identities and clinical
features. Only biopsies containing more than eight portal
tracts were read. Portal, peri-portal and lobular necro-
inflammatory activity (grading) and fibrosis (staging) were
investigated by applying Scheuers 1991 histological score
[41]. Liver steatosis was assessed as the percentage of
hepatocytes containing macrovescicular fat droplets. It was
coded as absent if 0 to 4%, or present if ‡ 5% of
hepatocytes were affected. Portal and peri-portal eosino-
philic leucocyte infiltrate was assessed in every portal tract
of haematoxylin ⁄ eosin stained sections. We counted eo-
sinophils in all portal tracts (at least eight) and reported in
the data-base the three highest values of eosinophils count.
The presence of 3 or more eosinophils in portal and peri-
portal space was considered relevant. We also investigated,
histological features more frequently reported to be related
to drug induced hepatitis, i.e. canalicular cholestasis,
peri-venular lipofuscinosis and small intra-lobular
granulomas.
Statistical methods
Continuous variables were summarized as mean ± SD and
categorical variables as frequency and percentage.
Significant differences between patients with or without
drug assumption were calculated using a chi-square
test for categorial variables and t Student test for contin-
uous variables. Multiple logistic regression models were
used to assess the relationship of steatosis, fibrosis and
eosinophilic infiltrate with demographics, history of drug
assumption, and metabolic and histological features of the
patients.
In the first model the dependent variable was steatosis
coded as 0 or absent if <5% of the hepatocytes were affected,
and 1 or present if ‡5% of the hepatocytes were affected.
As candidate risk factors for presence of histological steatosis
we selected age, gender, history of drug assumption, ALT, c-
GT and AP levels, cholesterol, triglycerides, HOMA-score, EI
(<3 vs at least three eosinophils observed), grading score (£ 1
vs >1 according to Scheuer score) and fibrosis score (1 vs
2–4 of Scheuer score).
In the second model the dependent variable was fibrosis
coded as 0 (stage 1 of fibrosis according to Scheuer score) or
1 (stage 2–4 according to Scheuer score). We considered as
explanatory variables age, gender, history of drug assump-
tion, platelet count, ALT, c-GT, AP, cholesterol, triglycerides,
HOMA-score, EI (<3 vs at least 3 eosinophils observed),
grading score (£ 1 vs >1 according to Scheuer) and steatosis
(<5% vs ‡5% of hepatocytes affected).
In the third model the dependent variable was EI coded
as absent (<3 eosinophils) or present (‡3 eosinophils).
We selected as possible related variables age, gender, drug
assumption, platelet count, eosinophil count, ALT, c-GT
levels, AP, cholesterol, triglycerides and HOMA-score.
Variables found to be associated with the dependent vari-
ables on univariate logistic regression at a probability
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threshold of <0.10 were included in multivariate logistic
regression models. Regression analysis was performed using
PRO LOGISTIC subroutine in SAS (SAS Institute, Inc., Cary,
NC, USA) [42].
RESULTS
Patients characteristics
Among the 335 patients who underwent liver biopsy, 147
patients satisfied inclusion ⁄ exclusion criteria and were
evaluated in our study. The clinical and histological features
of those 147 patients were similar to the remaining 188
patients.
The characteristics of the 147 patients are shown in
Table 1. The mean age was 51 ± 13 years. HCV genotype 1
was predominant (91%), and all other genotypes of HCV
[2,3,4] were present in the measure of 3% each. Thirty-eight
percent of patients had concomitant diseases and constantly
took medications: 14% of patients assumed antihypertensive
drugs for blood hypertension; 6% of patients assumed L-ti-
roxina for hypothyroidism, 4% of patients assumed ben-
zodiazepines for psychiatric disturbances, 4% of patients
assumed inhibitor protonic pump for ulcer-like dyspepsia;
3% and another 3% of patients assumed oral hypoglycaemic
drug and alpha blocker, respectively, for diabetes and pros-
tatic hypertrophy, and another 4% assumed various drugs
for various conditions.
Concerning the prevalence of allergic diseases in our ser-
ies, two patients were affected by allergic rhinitis occasion-
ally treated with anti-histaminic drugs, and another patient
had a history of asthmatic bronchitis periodically treated
with corticosteroid drugs.
Only two patients had a mild increase of blood eosinophil
count with values of 620 and 660 cells ⁄ mm3 respectively.
These two patients assumed no drugs and their liver biopsies
show no increase of eosinophils in the liver parenchyma.
Histological findings
Regarding the histological features, 40 patients (27%) had
mild inflammation, 84 (57%) had moderate inflammation
and 23 (16%) severe inflammation. Overall, 107 patients
(73%) had a Scheuers grading score of greater than one.
A moderate ⁄ severe fibrosis (Scheuers staging score ‡2)
was present in 99 patients (67%). Histological steatosis
was observed in 52 patients (35%). Hepatic eosinophilic
infiltrate (‡3 cells evaluated in the portal ⁄ periportal
spaces) was observed in 46 patients (31%). A canalicular
cholestasis was present in two patients though they nei-
ther took drugs nor showed eosinophilic infiltrate in portal
tracts. Peri-venular lipofuscinosis was present in three
patients and two of them were taking drug with EI in the
liver parenchyma. Small intra-lobular epithelioid granulo-
mas and epithelioid granuloma-like aggregates were
present in 31 patients (21% of cases), with no
differences between drug taking and not in drug taking
patients.
Table 1 Demographic, laboratory and histological features
of 147 patients with chronic hepatitis C
Mean age (years), mean ± sd 51 ± 13
Gender, n (%)
Male 74 (50.3)
Female 73 (49.6)
Genotypes HCV, n (%)
1 134 (91)
2 4 (3)
3 5 (3)
4 4 (3)
Patients with drug
assumption, n (%)
56 (38)
Antihypertensives 21 (14)
l-tiroxin 8 (6)
Benzodiazepin 6 (4)
Inhibitor protonic pump 6 (4)
Oral hypoglicaemic drug 5 (3)
Alfa-blocker 4 (3)
Other 6 (4)
ALT (UNL) 2.4 ± 2.0
Platelet count (·103 ⁄mm3) 206 ± 58
Eosinophils count (cells ⁄mm3) 184.9 ± 143.7
c-GT (UNL) 1.08 ± 0.8
Alkaline Phosphatase (UNL) 0.7 ± 0.2
Cholesterol mg ⁄ dL (n.v. £220) 177 ± 35 (43–294)
Triglycerides mg ⁄ dL (n.v. £175) 97 ± 47 (40–404)
Blood glucose (mM ⁄ L) 5.2 ± 1.33 (3.7–13.7)
Insulin (lU ⁄mL) 12.6 ± 7.2 (2.0–42.0)
HOMA-score 3.1 ± 2.3 (0.4–17.0)
Histology at biopsy (Scheuer score)
Grade of inflammation (code)
1 (0) 40 (27%)
2 (1) 84 (57%)
3 (1) 23 (16%)
Stage of fibrosis (code)
1 (0) 48 (33%)
2 (1) 71 (48%)
3 (1) 25 (17%)
4 (1) 3 (2%)
Steatosis
Absent (<5%) 95 (65%)
Present (‡5%) 52 (35%)
Eosinophilic infiltrate
Absent (<3 cells) 101 (69%)
Present (‡3 cells) 46 (31%)
Continuous variables: mean ± SD (minimum–maximum).
Categorial variables: absolute value (%). Abbreviations:
ALT, alanine aminotransferase; c-GT, c-glutamyltransferase;
UNL, upper normal limit; n.v., normal values.
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Comparison between patients with and without chronic
drug assumption
Table 2 shows the significant differences between patients
with and without history of drug assumption. The drug-
taking patients were 10 years older (P < 0.0001), had
higher ALT (P < 0.009) and alkaline phosphatase
(P < 0.003) levels, presented a more severe grading score
(P < 0.02), and a more frequent presence of EI
(P < 0.0001), but not of an elevated blood eosinophil count,
than non drug-taking subjects.
Factors associated with histological hepatic steatosis
We performed univariate and multivariate analyses to
identify risk factors associated with the presence of histo-
logical steatosis. The results are reported in Table 3.
At univariate analysis, drug assumption, ALT serum levels,
Table 2 Demographic, laboratory and
histological features of the 147 patients
in according to drug assumption
Variables
Patients without
drug assumption
(91)
Patients with
drug assumption
(56) P
Age (years) 48 ± 14 (18–69) 57 ± 9 (29–70) <0.0001
Gender (M ⁄ F) 46 ⁄45 28 ⁄28
ALT (UNL) 2.05 ± 1.4 2.9 ± 2.5 0.009
c-GT (UNL) 1.0 ± 0.7 1.22 ± 0.89 0.09
Alkaline phosphatase
(UNL)
0.63 ± 0.21 0.74 ± 0.23 0.003
Platelet count
(·103 ⁄mm3)
210.7 ± 59.5 199.4 ± 54.7 0.25
Eosinophil count
(cells ⁄mm3)
188 ± 152,2 180 ± 129.4 0.7
HOMA-IR 2.9 ± 2.6 3.3 ± 1.9 0.31
Histological features
Grading >1 60 (66%) 47 (84%) 0.02
Staging ‡2 56 (61.5%) 42 (75%) 0.1
Steatosis 28 (31%) 24 (43%) 0.18
Eosinophilic infiltrate 16 (17.6%) 30 (53.6%) <0.0001
Abbreviations: ALT, alanine aminotransferase; c-GT, c-glutamyltransferase; UNL,
upper normal limit; n.v., normal values.
Table 3 Univariate and multivariate analysis of risk factors for liver steatosis in 147 patient with chronic hepatitis C
Variable Univariate analysis Multivariate analysis
Independent P OR 95% C.I. P OR 95% C.I.
Age (years) 0.15 1.018 0.994–1.053
Sex (M ⁄ F) 0.52 0.724 0.361–1.451
Drug assumption 0.04 2.133 1.00–4.552 0.63 0.811 0.346–1.903
ALT–UNL 0.03 1.005 1.000–1.050 0.26 1.003 0.998–1.009
c-GT–UNL 0.16 0.99 0.98–1.002
AP–UNL 0.50 1.005 0.99–1.018
Cholesterol (mg ⁄ dL) 0.42 0.99 0.98–1.006
Triglycerides (mg ⁄ dL) 0.23 0.99 0.98–1.003
HOMA score 0.04 1.173 1.001–1.374 0.046 1.181 1.003–1.391
Eosinophilic Infiltrate <0.001 4.83 2.242–11.418 <0.0001 5.86 2.464–13.962
Grading 0.11 0.59 0.35–1.015
Staging 0.17 0.72 0.46–1.14
Abbreviations: ALT, alanine aminotransferase, c-GT, c-glutamyltransferase; AP, alkaline phosphatase; UNL, upper normal
limit.
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HOMA score and histological EI were significantly associated
with liver steatosis (P < 0.10). Multivariate analysis showed
that HOMA score (OR 1.18; 95% CI 1.00–1.39) and EI (OR
5.86; 95% CI 2.46–13.96) were independent and significant
risk factors for histological steatosis.
Factors associated with moderate ⁄ severe stage of fibrosis
Older age, platelet count, AP levels, EI and more severe
necroinflammation were significantly associated with mod-
erate ⁄ severe fibrosis in univariate analysis (P < 0.10).
Multivariate analysis showed that grading (OR 6.82; 95% CI
2.46–18.80) and EI (OR 4.00; 95% CI 1.23–12.90) were
independent and significant risk factors for moderate ⁄ severe
fibrosis (Table 4).
Variables associated with hepatic eosinophilic infiltrate
We even investigated even possible correlations between
demographics, history of drug assumption, biochemical
variables, blood eosinophil count, and the EI. The results are
reported in Table 5. Older age, drug assumption, high ALT
Table 4 Univariate and multivariate analysis of risk factors for moderate ⁄ severe stage of fibrosis in 147 patient with chronic
hepatitis C
Variable Univariate analysis Multivariate analysis
Indipendent P OR 95% CI P OR 95% CI
Age (years) 0.08 1.035 0.998–1.074 0.68 1.008 0.97–1.045
Gender (M ⁄ F) 0.42 0.581 0.298–1.557
Drug assumption 0.877 0.938 0.383–2.292
Platelet count (·103 ⁄ mm3) 0.07 0.99 0.98–1.001 0.29 0.99 0.98–0.004
ALT–UNL 0.11 0.99 0.98–1.001
c-GT–UNL 0.67 1.002 0.99–1.009
AP–UNL 0.045 0.98 0.97–1.00 0.46 1.007 0.980–1.025
Cholesterol (mg ⁄ dL) 0.96 1.00 0.98–1.01
Triglycerides (mg ⁄ dL) 0.12 1.007 0.98–1.014
HOMA-score 0.122 1.136 0.966–1.334
Eosinophilic infiltrate 0.06 2.31 0.98–5.478 0.02 4.00 1.23–12.9
Grading 0.0002 4.317 2.049–9.094 0.0002 6.82 2.46–18.8
Steatosis 0.69 1.25 0.54–2.92
Abbreviations: ALT, alanine aminotransferase; c-GT, c-glutamyltransferase; AP, alkaline phosphatase; UNL, upper normal
limit.
Table 5 Univariate and multivariate analysis of risk factors for hepatic eosinophilic infiltrate in 147 patient with chronic
hepatitis C
Variable Univariate analysis Multivariate analysis
Independent P OR 95% CI P OR 95% CI
Age (years) 0.001 1.057 1.022–1.094 0.08 1.040 0.994–1.089
Gender (M ⁄ F) 0.76 0.899 0.447–1.806
Drug assumption <0.0001 5.409 2.547–11.485 0.002 4.022 1.622–9.969
Platelet count (·103 ⁄ mm3) 0.70 0.999 0.992–1.005
Eosinophil count (c ⁄ mm3) 0.12 1.009 0.991–1.025
ALT–UNL 0.007 1.008 1.002–1.013 0.18 1.005 0.998–1.012
c-GT–UNL 0.06 1.007 1.000–1.015 0.595 1.003 0.993–1.013
AP–UNL 0.25 1.008 0.994–1.021
Cholesterol (mg ⁄ dL) 0.819 1.001 0.991–1.011
Triglycerides (mg ⁄ dL) 0.52 1.002 0.995–1.010
HOMA-score 0.825 1.017 0.874–1.184
Abbreviations: ALT, alanine aminotransferase; c-GT, c-glutamyltransferase; AP, alkaline phosphatase; UNL, upper normal
limit.
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and c-GT serum levels were significantly associated with the
presence of eosinophils in the liver tissue. The multivariate
analysis showed that only drug assumption (OR 4.02; 95%
CI 1.62–9.97) independently and significantly correlated
with the EI.
DISCUSSION
Recently there has been increasing interest in the role of
liver injury cofactors in the progression of chronic hepatitis
C, steatosis alcohol abuse and iron overload have been
identified as cofactors of liver damage [2,43]. Conversely
other variables, such as chronic drug assumption or con-
comitant chronic diseases have not been clearly estimated as
risk factors for the progression of liver damage. In the same
setting, the significance of hepatic eosinophilic infiltrate has
not been investigated.
Many experimental studies have shown that activated
eosinophils could play an important role in the pathogenesis
of the abovementioned liver diseases (PBC, PSC, human
hepatic allograft rejection, idiopathic hypereosinophilic
syndrome, graft-vs-host-disease) through release of granules
containing TNF-a, highly cytotoxic proteins such as major
basic protein and eosinophilic cationic protein [3–6,17–
26,44,45].
Several reports have described a hepatic EI in patients
with drug hepatotoxicity sustained by an immunoallergic
mechanism, and induced by anticonvulsivants (phenytoin,
carbamazepine) [30–32] and tenoxicam [33]. Recently,
some authors have studied the significance of liver EI in
patients with drug-induced liver injury [34]. The first
experimental model to prove in vivo eosinophils-induced
hepatotoxicity was established by Tsuda et al. in 2001. They
used IL-5 transgenic mice with a consequent blood hyper-
eosinophilia. These mice, after injection of lipopolysaccha-
ride (LPS), developed an extensive hepatic lobular necrosis
associated with a transmigration of eosinophils through
vascular endothelium and degranulation of cytotoxic gran-
ules in inflamed areas. These eosinophilic injuries were
transient, but liver specific. Pre-administration of gadolinium
chloride (GdCl3) and anti-TNF-a markedly reduced the he-
patic inflammation, suggesting that LPS-activated Kupffer
cells play a key role in producing the cytotoxicity of eosin-
ophils by releasing TNF-a [35]. More recently another study
by Takahashi et al. [36], found, with an immunohisto-
chemical technique, an increased expression of Ecalec-
tin ⁄ galectin-9 (ECL ⁄ GL9), an eosinophilic chemoattractant
isolated from T lymphocytes, specifically in liver biopsy of
patients with drug-induced liver injuries [37,38].
In consideration of this biological and clinical evidence
and of eosinophils potential capacity to induce liver injury,
we investigated this histological finding in HCV chronic pa-
tients, in relation to other clinical and histological features.
In our study we showed that drug-taking patients who
were significantly older than non drug-taking patients, and
with higher ALT and alkaline phosphatase levels, pre-
sented more severe necro-inflammatory activity and more
frequent EI in liver parenchyma than patients without
drug assumption. Moreover we found that the presence of
EI is strongly and independently associated with drug
assumption. Therefore we could speculate that the drug
assumption, more frequent in older patients, can induce
hepatic EI.
In multivariate analysis, we found a clear correlation be-
tween steatosis and EI. Histological hepatic steatosis is a very
frequent finding in chronic hepatitis C patients. It can be
identified as viral steatosis in genotype 3, and as metabolic
steatosis typically of non-3 genotypes [46]. IR represents the
pathogenetic key of metabolic steatosis [43,47,48], and dif-
ferent viral and non-viral mechanisms have been suggested
in its pathogenesis [49–51]. We could speculate that eosin-
ophils are able to induce steatosis by interfering with insulin
signaling via TNF-a [52,53].
Furthermore, in our study we found that liver fibrosis was
associated with EI, as well as with necroinflammatory
activity. The association between EI and liver fibrosis could
be explained by the eosinophils ability to release TNF-a and
other cytokines capable of increasing an inflammatory cas-
cade and therefore stimulating the fibrogenic activity of
stellate cells [54].
We have found no significant differences in the eosinophil
count in patients with or without EI and in patients with or
without drug assumption. So, in our study, the number of
eosinophils in liver samples was not correlated with the
number of eosinophils in the blood at the time of biopsy. This
is in keeping with the observation of Pham et al. [55], who
stated that the recruitment of eosinophils in the liver tissue
may depend on local mechanisms. Selective recruitment of
eosinophils in the liver of patients with drug-induced liver
disease may be related to the expression of specific chemo-
attractants.
This study presents the limits of a retrospective analysis,
particularly in the recruitment of cases. In fact, patients with
clearer anamnestic data were preferred, so a recall bias may
have been generated. Moreover the cut-off of three eosin-
ophils that we utilized to assign the presence of EI in liver
biopsy is arbitrary, with no previous specific reports in the
literature. We observed that number of eosinophils was
greater in the larger portal tracts, but as we considered the
feature eosinophilic infiltrate a dichotomous variable (0
or 1), these differences should not affect the meaning of the
study. Therefore we counted the eosinophils in all portal
tracts (at least eight) and we reported the three highest
values of eosinophil counts in our database.
Our evidence could be relevant for clinical management of
patients with hepatitis C and chronic drug assumption.
We have demonstrated the strong association between use of
drugs for common chronic diseases and EI, so for this cate-
gory of patients a histological assessment of liver disease may
be more opportune. In the future, a collection of consecutive
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cases in a prospective study should be performed to confirm
these findings.
In conclusion our study provides a prevalence estimate of
EI in the liver histo-morphology of patients with chronic
hepatitis C and documents its significant correlation with
liver injury caused by steatosis and fibrosis.
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